Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 486

1.
2.

Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bloodstream infections in United States medical centers (2015-2017).

Sader HS, Castanheira M, Streit JM, Flamm RK.

Diagn Microbiol Infect Dis. 2019 Jun 11:114850. doi: 10.1016/j.diagmicrobio.2019.06.002. [Epub ahead of print]

PMID:
31296360
3.
4.

Comparative Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Enterobacteriaceae Isolates Producing Extended-Spectrum β-Lactamases from U.S. Hospitals.

Castanheira M, Doyle TB, Mendes RE, Sader HS.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00160-19. doi: 10.1128/AAC.00160-19. Print 2019 Jul.

PMID:
31085510
5.

Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014-2015).

Pfaller MA, Sader HS, Shortridge D, Castanheira M, Flamm RK, Mendes RE.

J Chemother. 2019 Jul;31(4):188-194. doi: 10.1080/1120009X.2019.1609740. Epub 2019 May 13.

PMID:
31079589
6.

The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program.

Diekema DJ, Hsueh PR, Mendes RE, Pfaller MA, Rolston KV, Sader HS, Jones RN.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00355-19. doi: 10.1128/AAC.00355-19. Print 2019 Jul.

7.

Pharmacokinetic-Pharmacodynamic Evaluation of Ertapenem for Patients with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.

Bader JC, Lakota EA, Dale GE, Sader HS, Rex JH, Ambrose PG, Bhavnani SM.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00318-19. doi: 10.1128/AAC.00318-19. Print 2019 Jun.

PMID:
30962339
8.

Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia.

Bhavnani SM, Zhang L, Hammel JP, Rubino CM, Bader JC, Sader HS, Gelone SP, Wicha WW, Ambrose PG.

J Antimicrob Chemother. 2019 Apr 1;74(Supplement_3):iii35-iii41. doi: 10.1093/jac/dkz089.

9.

Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA and Europe (2014-17).

Carvalhaes CG, Sader HS, Flamm RK, Mendes RE.

J Antimicrob Chemother. 2019 Jul 1;74(7):1928-1933. doi: 10.1093/jac/dkz120.

PMID:
30932152
10.

Antimicrobial Susceptibility of Acinetobacter calcoaceticus-Acinetobacter baumannii Complex and Stenotrophomonas maltophilia Clinical Isolates: Results From the SENTRY Antimicrobial Surveillance Program (1997-2016).

Gales AC, Seifert H, Gur D, Castanheira M, Jones RN, Sader HS.

Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S34-S46. doi: 10.1093/ofid/ofy293. eCollection 2019 Mar.

11.

Variations in the Occurrence of Resistance Phenotypes and Carbapenemase Genes Among Enterobacteriaceae Isolates in 20 Years of the SENTRY Antimicrobial Surveillance Program.

Castanheira M, Deshpande LM, Mendes RE, Canton R, Sader HS, Jones RN.

Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S23-S33. doi: 10.1093/ofid/ofy347. eCollection 2019 Mar.

12.

Antimicrobial Susceptibility of Streptococcus pneumoniae from North America, Europe, Latin America, and the Asia-Pacific Region: Results From 20 Years of the SENTRY Antimicrobial Surveillance Program (1997-2016).

Sader HS, Mendes RE, Le J, Denys G, Flamm RK, Jones RN.

Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S14-S23. doi: 10.1093/ofid/ofy263. eCollection 2019 Mar.

13.

Antimicrobial Resistance Surveillance and New Drug Development.

Sader HS, Rhomberg PR, Fuhrmeister AS, Mendes RE, Flamm RK, Jones RN.

Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S5-S13. doi: 10.1093/ofid/ofy345. eCollection 2019 Mar.

15.
16.

Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016-2017).

Pfaller MA, Flamm RK, Duncan LR, Shortridge D, Smart JI, Hamed KA, Mendes RE, Sader HS.

Diagn Microbiol Infect Dis. 2019 Jul;94(3):304-313. doi: 10.1016/j.diagmicrobio.2019.01.015. Epub 2019 Jan 26.

PMID:
30808530
17.

Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres.

Sader HS, Mendes RE, Pfaller MA, Flamm RK.

J Antimicrob Chemother. 2019 May 1;74(5):1306-1310. doi: 10.1093/jac/dkz006.

PMID:
30753485
18.

In Vitro Activity of Tedizolid in Comparison with Other Oral and Intravenous Agents Against a Collection of Community-Acquired Methicillin-Resistant Staphylococcus aureus (2014-2015) in the United States.

Pfaller MA, Sader HS, Rhomberg PR, Flamm RK, Mendes RE.

Microb Drug Resist. 2019 Jul/Aug;25(6):938-943. doi: 10.1089/mdr.2018.0410. Epub 2019 Jan 29.

PMID:
30694735
19.

Low Prevalence of Gram-Positive Isolates Showing Elevated Lefamulin MIC Results during the SENTRY Surveillance Program for 2015-2016 and Characterization of Resistance Mechanisms.

Mendes RE, Paukner S, Doyle TB, Gelone SP, Flamm RK, Sader HS.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02158-18. doi: 10.1128/AAC.02158-18. Print 2019 Apr.

PMID:
30670418
20.

Antibacterial Activity of Lefamulin against Pathogens Most Commonly Causing Community-Acquired Bacterial Pneumonia: SENTRY Antimicrobial Surveillance Program (2015-2016).

Paukner S, Gelone SP, Arends SJR, Flamm RK, Sader HS.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02161-18. doi: 10.1128/AAC.02161-18. Print 2019 Apr.

PMID:
30670415
21.

Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015-2017) isolates from hospitalized patients with pneumonia in US medical centers.

Carvalhaes CG, Castanheira M, Sader HS, Flamm RK, Shortridge D.

Diagn Microbiol Infect Dis. 2019 May;94(1):93-102. doi: 10.1016/j.diagmicrobio.2018.11.021. Epub 2018 Nov 30.

PMID:
30642717
22.

Antimicrobial Activity of Omadacycline Tested against Clinical Bacterial Isolates from Hospitals in Mainland China, Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016).

Carvalhaes CG, Huband MD, Reinhart HH, Flamm RK, Sader HS.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e02262-18. doi: 10.1128/AAC.02262-18. Print 2019 Mar.

23.

In vitro activity of telavancin against Staphylococcus aureus causing pneumonia or skin and skin structure infections with concomitant bloodstream infections in United States hospitals (2012-2016).

Duncan LR, Flamm RK, Sader HS, Mendes RE.

Diagn Microbiol Infect Dis. 2019 Feb;93(2):167-170. doi: 10.1016/j.diagmicrobio.2018.09.011. Epub 2018 Oct 2.

24.

Frequency and antimicrobial susceptibility of bacterial isolates from patients hospitalised with community-acquired skin and skin-structure infection in Europe, Asia and Latin America.

Sader HS, Streit JM, Carvalhaes CG, Huband MD, Pfaller MA.

J Glob Antimicrob Resist. 2019 Jun;17:103-108. doi: 10.1016/j.jgar.2018.11.013. Epub 2018 Nov 17.

PMID:
30458298
25.

Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016.

Pfaller MA, Flamm RK, Mendes RE, Streit JM, Smart JI, Hamed KA, Duncan LR, Sader HS.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01566-18. doi: 10.1128/AAC.01566-18. Print 2019 Jan.

26.

Antimicrobial activity of ceftaroline and comparator agents tested against organisms isolated from patients with community-acquired bacterial pneumonia in Europe, Asia, and Latin America.

Sader HS, Flamm RK, Streit JM, Carvalhaes CG, Mendes RE.

Int J Infect Dis. 2018 Dec;77:82-86. doi: 10.1016/j.ijid.2018.10.004. Epub 2018 Oct 10.

27.

Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime-avibactam.

Atkin SD, Abid S, Foster M, Bose M, Keller A, Hollaway R, Sader HS, Greenberg DE, Finklea JD, Castanheira M, Jain R.

Infect Drug Resist. 2018 Sep 17;11:1499-1510. doi: 10.2147/IDR.S173804. eCollection 2018.

28.

Evaluation of the Revised Ceftaroline Disk Diffusion Breakpoints When Testing a Challenge Collection of Methicillin-Resistant Staphylococcus aureus Isolates.

Sader HS, Rhomberg PR, Doyle TB, Flamm RK, Mendes RE.

J Clin Microbiol. 2018 Nov 27;56(12). pii: e00777-18. doi: 10.1128/JCM.00777-18. Print 2018 Dec.

29.

Antimicrobial Susceptibility of Pseudomonas aeruginosa to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by U.S. Census Divisions: Results from the 2017 INFORM Program.

Sader HS, Flamm RK, Carvalhaes CG, Castanheira M.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01587-18. doi: 10.1128/AAC.01587-18. Print 2018 Dec.

30.

Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015-17).

Sader HS, Castanheira M, Mendes RE, Flamm RK.

J Antimicrob Chemother. 2018 Nov 1;73(11):3053-3059. doi: 10.1093/jac/dky279.

PMID:
30060117
31.

Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16.

Pfaller MA, Mendes RE, Duncan LR, Flamm RK, Sader HS.

J Antimicrob Chemother. 2018 Oct 1;73(10):2748-2756. doi: 10.1093/jac/dky235.

PMID:
29982565
32.

Murepavadin activity tested against contemporary (2016-17) clinical isolates of XDR Pseudomonas aeruginosa.

Sader HS, Flamm RK, Dale GE, Rhomberg PR, Castanheira M.

J Antimicrob Chemother. 2018 Sep 1;73(9):2400-2404. doi: 10.1093/jac/dky227.

PMID:
29901750
33.
34.

Antimicrobial Activity of Murepavadin Tested against Clinical Isolates of Pseudomonas aeruginosa from the United States, Europe, and China.

Sader HS, Dale GE, Rhomberg PR, Flamm RK.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00311-18. doi: 10.1128/AAC.00311-18. Print 2018 Jul.

35.

ZAAPS programme results for 2016: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 42 countries.

Mendes RE, Deshpande L, Streit JM, Sader HS, Castanheira M, Hogan PA, Flamm RK.

J Antimicrob Chemother. 2018 Jul 1;73(7):1880-1887. doi: 10.1093/jac/dky099.

PMID:
29659858
36.

Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014.

Pfaller MA, Sader HS, Flamm RK, Castanheira M, Mendes RE.

Diagn Microbiol Infect Dis. 2018 Jun;91(2):199-204. doi: 10.1016/j.diagmicrobio.2018.01.029. Epub 2018 Feb 3.

PMID:
29567128
37.

Assessment of 30/20-Microgram Disk Content versus MIC Results for Ceftazidime-Avibactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa.

Sader HS, Rhomberg PR, Huband MD, Critchley IA, Stone GG, Flamm RK, Jones RN.

J Clin Microbiol. 2018 May 25;56(6). pii: e01960-17. doi: 10.1128/JCM.01960-17. Print 2018 Jun.

38.

Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016).

Pfaller MA, Huband MD, Streit JM, Flamm RK, Sader HS.

Int J Antimicrob Agents. 2018 Jun;51(6):848-853. doi: 10.1016/j.ijantimicag.2018.01.006. Epub 2018 Feb 2.

PMID:
29410368
39.

Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015).

Pfaller MA, Flamm RK, Duncan LR, Streit JM, Castanheira M, Sader HS.

Diagn Microbiol Infect Dis. 2018 May;91(1):77-84. doi: 10.1016/j.diagmicrobio.2017.12.020. Epub 2018 Jan 3.

40.

Erratum for Pfaller et al., "In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014".

Pfaller MA, Sader HS, Rhomberg PR, Flamm RK.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e02383-17. doi: 10.1128/AAC.02383-17. Print 2018 Feb. No abstract available.

41.

Antimicrobial activity of oritavancin and comparator agents when tested against Gram-positive bacterial isolates causing infections in cancer patients (2014-16).

Pfaller MA, Sader HS, Castanheira M, Flamm RK, Mendes RE.

J Antimicrob Chemother. 2018 Apr 1;73(4):916-922. doi: 10.1093/jac/dkx485.

PMID:
29294031
42.

Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).

Pfaller MA, Flamm RK, Castanheira M, Sader HS, Mendes RE.

Int J Antimicrob Agents. 2018 Apr;51(4):608-611. doi: 10.1016/j.ijantimicag.2017.12.011. Epub 2017 Dec 23.

PMID:
29277526
43.

Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical Centers.

Sader HS, Mendes RE, Duncan LR, Pfaller MA, Flamm RK.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e02397-17. doi: 10.1128/AAC.02397-17. Print 2018 Mar.

44.

Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.

Castanheira M, Duncan LR, Mendes RE, Sader HS, Shortridge D.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e02125-17. doi: 10.1128/AAC.02125-17. Print 2018 Mar.

45.
46.

In Vitro Activities of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from U.S. Hospitals: Results from Seven Years of the AWARE Surveillance Program (2010 to 2016).

Pfaller MA, Mendes RE, Duncan LR, Flamm RK, Sader HS.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01555-17. doi: 10.1128/AAC.01555-17. Print 2018 Feb.

47.

The application of in vitro surveillance data for antibacterial dose selection.

Flamm RK, Sader HS, Castanheira M, Jones RN.

Curr Opin Pharmacol. 2017 Oct;36:130-138. doi: 10.1016/j.coph.2017.10.009. Epub 2017 Nov 11. Review.

PMID:
29136540
48.

Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates.

Sader HS, Mendes RE, Pfaller MA, Shortridge D, Flamm RK, Castanheira M.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01856-17. doi: 10.1128/AAC.01856-17. Print 2018 Jan.

49.
50.

In Vitro Activity of the Novel Lactone Ketolide Nafithromycin (WCK 4873) against Contemporary Clinical Bacteria from a Global Surveillance Program.

Flamm RK, Rhomberg PR, Sader HS.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01230-17. doi: 10.1128/AAC.01230-17. Print 2017 Dec.

Supplemental Content

Loading ...
Support Center